Conclusion of non-exclusive discount contracts in accordance with Section 130a (8) SGB V for drugs with the active ingredient nilotinib (L01XE08) within the period from October 1, 2020 to September 30, 2022 with the option of concluding a contract at any time (open-house model).
The AOK Rhineland-Palatinate / Saarland:
- The health insurance company offers all interested pharmaceutical companies without a selection decision discount agreements with the active ingredient nilotinib (L01XE08). Contracts are concluded as part of an “open house model”. The contracts offered are not exclusive; Contracts with all market participants (pharmaceutical companies) are on the part of the AOK Rheinland-Pfalz / Saarland.
- Wanted the health insurance. In the open house model, uniform conditions apply to all participants. The content of the contract, terms and conditions and access procedures are uniform - individual negotiations are not conducted.
The contract periods are a maximum of 24 months, the earliest contract start is October 1st, 2020. All contracts end at the latest 24 months after the date of the earliest start of the contract, regardless of the date on which the contract was concluded. Joining or entering into a contract can take place within the 24-month period on the first of each month.
There is a right of termination 6 weeks at the end of each month in accordance with the provisions of the contract. Further information on the termination options can be found in the contract documents.
The AOK Rhineland-Palatinate / Saarland:
- The health insurance company reserves the right to replace the non-exclusive open house discount agreements with exclusive discount agreements as part of Europe-wide tendering procedures during the contract period. With the entry into force of advertised, exclusive discount contracts, the open house contracts are terminated in accordance with the contractual provisions, ie the open house contracts end automatically.
Interested pharmaceutical companies can request the participation documents and the contract documents from the contact address given under I.1). Contracts for the active ingredient nilotinib (L01XE08) will be concluded for the first time with effect from October 1, 2020. Interested parties who would like to become a contractual partner on this date have the contract documents to be submitted to the AOK Rhineland-Palatinate / Saarland by August 31, 2020.
- Submit the health insurance. It is accessed by the AOK Rheinland-Pfalz / Saarland.
- The health insurance company.
Note: The first award in this procedure will be granted no earlier than 10 calendar days after the publication of this EU announcement in the Official Journal. Later contracts can be concluded for the first of a month during the 24-month maximum term. If you are interested in becoming a contractual partner on these follow-up dates, the receipt of the contract documents, including Appendix 1, must be submitted no later than the end of the month that precedes the previous month of the desired start of the contract (e.g. receipt April 30th when the contract starts June 1st). The exact entry deadlines will be announced with the contract documents. This publication is not a public contract within the meaning of the procurement coordination directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are mandatory for legal reasons.